Glaucoma: who works on it

One card per institution. Pick a target to see only the groups that work on it.

• All targets
• VEGF 1
• NRF2 0
• PI3K 0
• STAT3 0
• AMPK 0
• MAPK 0
• AKT 0
• GLP-1 1
• NLRP3 0
• STING 0
• TNF 0
• IL-1 0
• JAK 0
• MMP-9 1
• PPAR 0
• SIRT1 0
• TP53 0
• ACE2 0
• GPX4 0
• IL-6 1
• mTOR 0
• YAP 0
• APOE 0
• BDNF 0
• CD38 0
• CGRP 0
• COX-2 0
• ERK 0
• GIP 0
• HSP90 0
• IL-17 0
• MEK 0
• MYCN 0
• NF1 0
• NMDA 0
• PDGFR 0
• RANKL 0
• RB1 0
• TIM-3 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Next-generation therapeutics for vascular diseases (TIE2gether)

  Helsingin Yliopisto· Helsinki, Finland· EU contribution €4,273,568· until Jan 2031· 7 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Tailored lipid nanoparticles for iontophoretic ocular drug delivery. (ODiN)

  Universita Degli Studi di Parma· Parma, Italy· EU contribution €193,643· until Jan 2029· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Peptidomimetic therapy to promote central Nervous System repair (POPEYE)

  Institut National de la Sante Et de la Recherche Medicale· Paris, France· EU contribution €150,000· until Jun 2027

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Pharmacological and gene therapy targeting of NMNAT2 for neuroprotection in glaucoma (TARGET-NMNAT2)

  Karolinska Institutet· Stockholm, Sweden· EU contribution €2,261,875· until Sept 2030

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Nanoparticle-mediated ocular delivery of novel NAD-boosting small molecules for ophthalmic disease. (NanoNAD)

  Karolinska Institutet· Stockholm, Sweden· EU contribution €252,180· until Mar 2027

5 of 8 running projects, newest first. Listed amounts together: €14.2m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 8
• Organoids 2
• Mendelian Randomization Analysis 24
• CRISPR-Cas Systems 3
• Gene Expression Profiling 15
• Sequence Analysis, RNA 1
• Exome Sequencing 16
• Proteomics 21
• Metabolomics 11
• Mass Spectrometry 4
• Flow Cytometry 7
• Immunohistochemistry 17
• Magnetic Resonance Imaging 22
• Machine Learning 27
• Deep Learning 35
• Cohort Studies 24
• Genome-Wide Association Study 29

• Pathological P-Selectin Upregulation Promotes Retinal Ganglion Cell Degeneration Accompanied by T-Cell Recruitment in Glaucoma.

  Invest Ophthalmol Vis Sci, Aug 2026

• Histomorphologic and immunohistochemical characteristics of intraocular metastatic carcinomas of presumed pulmonary origin in cats: A retrospective case series from 2019 to 2025.

  Vet Pathol, May 2026

• Integrin α2 Level is a Critical Determinant for Mesenchymal to Endothelial Phenotype Transition of Trabecular Meshwork Cells.

  Curr Eye Res, May 2026

• Identification of Brimonidine as a Novel Substrate of Organic Cation Transporters OCT2 and MATE1 Expressed in Human Eye.

  Invest Ophthalmol Vis Sci, Apr 2026

• TXNDC5 in POAG: Promoting Extracellular Matrix Protein Accumulation and Raising Intraocular Pressure.

  Invest Ophthalmol Vis Sci, Apr 2026

• Neuritin1 Cis-Regulatory Elements Enable Gene Expression Preferentially in Retinal Ganglion Cells.

  Invest Ophthalmol Vis Sci, Apr 2026

• Optic Nerve Head Spatial Transcriptomic Change in Nonhuman Primate Early Experimental Glaucoma.

  Invest Ophthalmol Vis Sci, Mar 2026

• Targeting CRBN With Thalidomide Suppresses Fibrosis After Glaucoma Drainage Surgery Through NF-κB Pathway Inhibition.

  Invest Ophthalmol Vis Sci, Mar 2026

• [Remodelling of the lamina cribrosa of the sclera in optic nerve axonal injury].

  Vestn Oftalmol, Jan 2026

• SIRT1 is required for the neuroprotection of resveratrol on retinal ganglion cells after retinal ischemia-reperfusion injury in mice.

  Graefes Arch Clin Exp Ophthalmol, Jan 2020

See which targets of this disease your abstract mentions, and go to the people working on them.